Cefmenoxime Hydrochloride for Injection Instructions
Release time:
2020-07-31
Approval Date: March 29, 2007
First Amendment Date: September 16, 2009
Second Amendment Date: December 01, 2013
Third Amendment Date: October 31, 2014
Fourth Amendment Date: December 01, 2015
Fifth Amendment Date: december 03, 2015
Cefmenoxime Hydrochloride for Injection Instructions
Please read the instructions carefully and use
[Drug Name]
General Name: Cefmenoxime Hydrochloride for Injection
English Name: Cofmenoxime Hydrochloride for Injection
Chinese Pinyin: Zhusheyong Yansuan Toubaojiawo
[Ingredients] The main ingredient of this product is Cefmenoxime Hydrochloride, whose chemical name is:(6R,7R) -7-[(Z)-2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido]-3-[[(1-methyl-1H-tetrazol-5-yl)-thio] methyl]-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-Formic acid hydrochloride (2:1).
chemical structural formula:
molecular formula:(C16H17N9O5S3)2 · HCl molecular weight: 1059.58 auxiliary material: anhydrous sodium carbonate
[properties] this product is white to light yellow crystal or crystalline powder.
[Indications] This product is applicable to cefmenoxime-sensitive Streptococcus (except Enterococcus), Streptococcus pneumoniae, Digestococcus, Digestococcus, Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Haemophilus influenzae, Bacteroides, etc. caused by the following infections:
1, pneumonia, bronchitis, bronchiectasis complicated with infection, secondary infection of chronic respiratory diseases; Lung abscess, empyema;
2, pyelonephritis, cystitis; Bartholin's adenitis, endometritis, uterine adnexitis, pelvic inflammation, parauterine tissue inflammation;
3, cholangitis, cholecystitis, liver abscess; Peritonitis;
4, secondary infection of burns and surgical trauma;
5;
6. Cerebrospinal meningitis.
[Specifications] 0.25g, 0.5g, 1.0g, 2.0g (by C16H17N9O5S3)
[Usage and Dosage] Usage: This product is dissolved in 0.9 sodium chloride injection or glucose injection for intravenous drip.
In addition, for adults, 0.5g-2g of this product can also be added to the rehydration of sugar solution, electrolyte solution or amino acid preparation for intravenous drip within 30 minutes to 2 hours. For children, one dose can also be considered to be added to the fluid infusion, and intravenous drip is carried out within 30 minutes to 1 hour. For static injection, inject about 5ml of dissolved solution into the bottle for dissolution when using 1g, and inject not less than 100ml of dissolved solution into the bottle for drip.
Dosage: 1. Adults: mild infection: 1-2g a day, divided into 2 intravenous drips; Moderate and severe infection: it can be increased to 4g a day, divided into 2-4 intravenous drips. The dose can also be adjusted according to the clinical situation. 2. Children: mild infection: 40-80mg per kilogram of body weight per day, divided into 3-4 times of intravenous drip; Moderate and severe infection: it can be increased to 160mg per kilogram of body weight per day, divided into 3-4 times of intravenous drip; Cerebrospinal meningitis: it can be increased to 200mg per kilogram of body weight per day, divided into 3-4 times of intravenous drip.
[Adverse Reactions] 1. Serious Adverse Reactions:
⑴ Sometimes Shock (less than 0.1%) is caused. Therefore, careful observation should be made. In case of abnormal symptoms such as discomfort, abnormal feeling in mouth, wheezing, vertigo, defecation, tinnitus, sweating, etc., administration should be stopped and appropriate treatment should be carried out.
(2) Occasionally, severe renal dysfunction such as acute renal insufficiency (less than 0.1%), so renal function should be checked regularly and carefully observed. If abnormal, drug administration should be stopped and appropriate treatment should be carried out.
(3) Sometimes granulocytopenia (less than 0.1-5%) or no granulocytosis (less than 0.1). In addition, other cephalosporin antibiotics have been reported to cause hemolytic anemia. In case of abnormality, administration should be stopped and appropriate management should be carried out. Severe colitis with bloody stool, such as pseudomembranous colitis, sometimes occurs (less than 0.1 percent), such as abdominal pain and repeated diarrhea, should be stopped immediately and managed appropriately.
(5) Interstitial pneumonia and PIE syndrome (less than 0.1 percent) with fever, cough, dyspnea, chest X-ray abnormalities, eosinophilia, etc., should be discontinued and managed appropriately.
(6) In patients with renal insufficiency, spasticity and the like are sometimes caused when a large amount of drugs are administered.
2, Other Adverse Reactions
⑴ Allergy: Rash, Urticaria, Erythema, Pruritus, Fever, Lymphadenopathy, Arthralgia;
⑵ Blood: Anemia, Eosinophilia, Thrombocytopenia;
(3) Liver: ALT, AST, ALP, LDH Elevation, Jaundice, γ-GTP Elevation;
(4) Digestive Tract);
(5) Flora disorder: stomatitis, candidiasis;
(6) Vitamin deficiency: vitamin K deficiency symptoms (hypocoagulinemia, bleeding tendency, etc.), vitamin B deficiency symptoms (glossitis, stomatitis, loss of appetite, neuritis, etc.);
(7) Others: burnout, staggering, headache.
[Taboo] The product and cephalosporins have a history of allergic reactions are prohibited.
[Precautions] 1. The following patients take drugs carefully
(1) Patients with a history of allergy to penicillin antibiotics;
(2) I or my parents and brothers have patients who are prone to allergic symptoms such as bronchial asthma, rash, urticaria, etc.
(3) Patients with severe renal dysfunction (continuous increase of blood drug concentration may occur);
(4) Elderly Patients (Decline in Physiological Function, side effects are easy to occur; Sometimes vitamin K deficiency and bleeding tendency);
(5) people with poor oral feeding or intravenous nutrition, and people with poor general state (sometimes vitamin K deficiency can be caused, so careful observation should be made);
2, because shock reaction may occur, so detailed consultation is required. It is recommended to do skin allergy test before injection. First aid should be done in advance in the event of shock.
3, the use of this product, the best regular liver function, kidney function, blood and other tests.
4. Interference to diagnostic reagents: In addition to the reaction of urine sugar test strip (TES-tape), false positive reaction may occur when urine sugar test is carried out with Banns reagent, Flynn reagent and Clinitest (sheet reagent containing copper sulfate), and direct antiglobulin (Coombs) test is positive, please pay attention.
[Medication for pregnant and lactating women] The safety of medication for pregnancy has not been established, and the use of this product by pregnant and lactating women should be weighed.
[Use in children] The safety of use in preterm infants and newborns is uncertain.
[Elderly medication] Most elderly patients have decreased physiological functions and are prone to side effects. Sometimes vitamin K deficiency and bleeding tendency.
[Drug Interactions]
1. Furananilic Acid Diuretics: It has been reported that renal dysfunction can be aggravated when combined with other cephalosporins. Therefore, renal function should be paid attention to when combined.
2. Ethanol (drinking): alcohol intake due to drinking, sometimes flushing, nausea, tachycardia, hyperhidrosis, headache, etc., so alcohol intake should be avoided during and at least one week after medication.
[Drug Overdose] Unclear
[Pharmacology and Toxicology] Pharmacological Effects
Cefmenoxime is a semi-synthetic cephalosporin broad-spectrum antibiotic that achieves bactericidal effects by inhibiting the biosynthesis of bacterial cell walls. This product has a strong antibacterial effect on gram-negative bacteria due to its good extracellular membrane permeability, stability to β-lactamase, and strong affinity to penicillin binding proteins (PBPs)1A, 1B and 3, which has a strong barrier to the formation of cell wall mucin cross-linking.
In vitro tests show that this product has an effect on both gram-positive and gram-negative bacteria. The antibacterial activity of Gram-positive bacteria was stronger than that of cefotiam (CTM) and cefazolin (CEZ) in terms of Streptococcus pyogenes and Streptococcus pneumoniae. It has strong antibacterial power against digestive cocci and digestive streptococcus. The antibacterial power to Gram-negative bacteria was slightly stronger than CTM and much stronger than CEZ in terms of E. coli and pneumoniae. The antibacterial force against influenza bacilli, Proteus, Serratia marcescens, Citrobacter, and intestinal bacteria was stronger than CTM, and much stronger than CEZ. In addition, it also shows strong antibacterial power to Bacteroides.
Toxicology study Reproductive toxicity: Animal experiments showed that in rats, rabbits and monkeys during the organ formation period of administration, each administration group of rabbits had female rabbit death or abortion, but all kinds of animals had no teratogenic effect. There was no obvious abnormality in general reproductive toxicity test and perinatal reproductive toxicity test in rats. [Pharmacokinetics] According to literature data, the peak blood drug concentration can reach 50.9mg/L and 135.7mg/L respectively after a single intravenous infusion of 0.5g and 1g of this drug in adults with normal renal function, and 75mg/L and 125mg/L respectively after a single intravenous infusion of 0.5g and 1g of cefmenoxime. The serum elimination half-life of this product is about 1 hour. It is well distributed in various tissues and body fluids after administration. It can also cross the blood-brain barrier. The drug is mainly excreted through the kidney. After an intravenous injection or intravenous drip of 0.5g, 1g and 2g of the drug in adults (with normal renal function), the excretion rate in urine within 6 hours is 60-82%. In addition, the urine drug concentration after 1g of intravenous drip was about 4400 μg/L for 0-2 hours, about 750 μg/L for 2-4 hours, and about 120 μg/L for 4-6 hours. Children (with normal renal function) had the same urinary excretion rate at 6 hours after a single intravenous injection or intravenous drip of 10, 20, and 40 mg/kg as adults.
[Storage] Shaded, airtight, and stored in a cool and dry place (not more than 20 ℃).
[Package] Antibiotic Glass Bottle, 0.25g × 2 Bottle/Box, 0.25g × 1 Bottle/Box; 0.5g × 1 bottle/box, 0.5g × 2 bottle/box; 1.0g × 1 bottle/box; 2.0g × 2 bottles/box, 2.0g × 1 bottle/box; 0.25g × 5 bottles/box, 0.5g × 5 bottles/box, 1.0g × 5 bottles/box.
[Validity Period] 24 Months
[Implementation Standard] "Chinese Pharmacopoeia" 2015 Edition II
[Approval Document No.] Chinese Medicine Standard H20041145( 0.25g), Chinese Medicine Standard H20041146( 0.5g), Chinese Medicine Standard H20041147(1.0g), Chinese Medicine Standard H20093940( 2.0g)
[Production Enterprise] Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd. Address: no. 58, Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax: 0579-82661998 Postal Code: 321075
Website:
www.zjjfyy.com.cn
More information
Shanghai North Carolina passed the "Little Giant" annual acceptance
Recently, Shanghai Beika Pharmaceutical Technology Co., Ltd., a new member of Jianfeng Pharmaceutical Co., Ltd., successfully passed the annual acceptance of Shanghai science and technology "little giant" cultivation enterprise. In order to promote the independent innovation of enterprises, improve the core competitiveness of enterprises, enhance the competitive advantage of enterprises in domestic and foreign industries, and speed up the construction of scientific and technological innovation, Shanghai North Carolina applied for the Shanghai "Science and Technology Innovation Action Plan" science and technology "little giant" cultivation project in 2016 and was approved, becoming a member of 87 "little giant" cultivation enterprises in Shanghai in that year, with a project implementation period of 2 years. During the period of the Little Giant Cultivation Project, North Carolina completed the re-identification of Shanghai high-tech enterprises and the identification of Songjiang District Enterprise Technology Center. Songjiang District Enterprise Technology Center was evaluated as excellent, passed the certification of Shanghai Academician Expert Workstation, and passed the acceptance of Shanghai Patent Work Pilot Enterprises. A total of 4 invention patents were authorized, 12 invention patents were applied, 2 registered trademarks were applied, and 4 enterprise standards were formulated, there are 22 product testing reports. In 2017, Songjiang District's industry-university-research innovation project was approved and the project target was completed. Tinib drugs and their intermediates in non-small cell lung cancer (NSCLC) are the dominant varieties in North Carolina. In order to improve the existing tinib product line and consolidate the economic benefits and market share of this kind of products, North Carolina has not only conducted research and development on the latest generation of precision medical special-effect drugs such as cabozantinib (Cabozantinib) and ceritinib (Ceritinib), but also focused on the development of drug intermediates for tinib stars, which are hot spots in the pre-clinical research and development of generic drugs.
2020
07-31
The company held the 2017 Board of Directors and the Board of Supervisors
On April 20, Jiang Xiaomeng, chairman of the group company, presided over the 3rd meeting of the 10th board of directors of the company, and deliberated and passed 15 proposals and reports including the 2017 work report of the board of directors and the 2017 work report of the general manager. The general manager's report pointed out that in 2017, the company focused on the general work policy of "grasping trends, precise development, strengthening standards, improving quality, improving management, and enhancing efficiency", grasping the opportunities brought by economic structure optimization and industrial upgrading, and accelerating innovation Development, in-depth management integration, continuous improvement of management level, improvement of enterprise operation efficiency, strengthening of marketing expansion, and steady promotion of product sales growth, remarkable results have been achieved in technological innovation and technological transformation, the financial structure has been continuously improved, and the core competitiveness of enterprises has been further strengthened. The company achieved operating income of 2.827 billion yuan for the whole year, an increase of 18.81 percent over the same period last year, and realized net profit attributable to owners of the parent company of 348.4943 million yuan, an increase of 22.18 percent over the same period last year, another record high, with earnings per share of 1.01 yuan, achieving the best operating performance in the peak 60-year development process. Total assets at the end of the year were 4.176 billion yuan, an increase of 4.53 percent over the same period last year. In 2017, with the in-depth implementation of the national "One Belt One Road" initiative, cement off-peak production has been comprehensively promoted, industry environmental protection supervision has been further improved, energy conservation and consumption reduction supervision has become stricter, mergers and acquisitions have deepened, industry self-discipline awareness has continued to increase, and the cement industry supply-side structural reform has started.
2020
07-31
The peak represents the two sessions of Jinhua
From March 30 to April 3, March 31 to April 4, the second session of the seventh session of the Jinhua CPPCC and the third session of the seventh session of the Jinhua Municipal people's Congress were held successively. Three deputies to the National People's Congress and members of the CPPCC attended the meeting and actively offered suggestions and suggestions for the future development of Jinhua. Among the three performance suggestions put forward by Jiang Xiaomeng, chairman of the group company, two are about the real economy. He said that the development of the real economy in Jinhua City has encountered many bottlenecks in recent years. On the one hand, the operating costs of real enterprises have increased year by year and the profits have decreased, which has affected the development confidence and investment enthusiasm of entrepreneurs; on the other hand, the current new economic concepts are emerging one after another, and social capital is emerging. The loss of reality has caused a greater impact on the real economy. To this end, Jiang Xiaomeng suggested starting from five aspects to help Jinhua's real economy get rid of its predicament, that is, to create a good environment for investment and enterprises to enter households, such as competitive land elements, supporting public environmental protection facilities, and reasonable supporting industries. Development policies, abundant labor resources, etc.; the government conducts in-depth research on land, factories, taxes, subsidies, incentives, etc, further introduce various preferential policies and measures that are attractive and can stimulate the economic vitality of real enterprises; the combination of government investment promotion and "business investment promotion", and introduce corresponding guidance and incentive policies, through the introduction of business in gold enterprises, it is more convincing and easier to succeed; pay attention to helping existing local industrial enterprises and enhance their enthusiasm; vigorously promote outstanding business operators and entrepreneurs, and create a good atmosphere of respect for entrepreneurs, to boost the enthusiasm of the majority of entrepreneurs to invest in the construction of return home. About Small and Micro Enterprises
2020
07-31
Determination of "60th Anniversary of Entrepreneurship" Series of Activities
In 1958, the first batch of peak people started from scratch and began to build the first cement plant in Jinhua at the foot of peak mountain. Today, 60 years later, the small cement plant has developed into a cross industry and cross regional listed company. In order to commemorate the 60th anniversary of Jianfeng's entrepreneurship, the company decided to organize a series of activities. The activity plan has been basically determined by the group company's office meeting, and an activity leading group led by Jiang Xiaomeng, chairman of the group company, has been established. The group office meeting discussed and decided that the commemorative activities are based on the principles of grand, simple and meaningful. While enlivening the company's cultural atmosphere, concentrating efforts, and enhancing the friendship and exchange of all employees, it also inherits and carries forward the essence of corporate culture accumulated over a long period of time. In order to carry out the activity smoothly, the company decided to set up a leading group for the celebration of the 60th anniversary of entrepreneurship, with Jiang Xiaomeng, chairman of the group company, as the group leader and Yu Jianhong, general manager of the group company, as the deputy group leader. The group members include Huang Jinlong, Zhang Fengliang, Xiang Chongping, Chen Tianci, Zhu Jianwei, Lan Xiaolong and Qin Xuping. There is a celebration working group. The series of commemorative activities mainly include media publicity with the theme of "publicizing peak achievements and establishing peak image"; carrying out manuscripts, calligraphy, painting, photography, speeches and other activities with the theme of "knowing peak and loving peak" and the history of Jianfeng Group's entrepreneurial development as the content; a series of cultural and sports activities with the theme of "strengthening physique and revitalizing peak; the activity of" sending warmth "with the theme of" caring for employees and caring for employees "; the group company with the theme of" infinite scenery at the peak"
2020
07-31
Determination of "60th Anniversary of Entrepreneurship" Series of Activities
In 1958, the first batch of peak people started from scratch and began to build the first cement plant in Jinhua at the foot of peak mountain. Today, 60 years later, the small cement plant has developed into a cross industry and cross regional listed company. In order to commemorate the 60th anniversary of Jianfeng's entrepreneurship, the company decided to organize a series of activities. The activity plan has been basically determined by the group company's office meeting, and an activity leading group led by Jiang Xiaomeng, chairman of the group company, has been established. The group office meeting discussed and decided that the commemorative activities are based on the principles of grand, simple and meaningful. While enlivening the company's cultural atmosphere, concentrating efforts, and enhancing the friendship and exchange of all employees, it also inherits and carries forward the essence of corporate culture accumulated over a long period of time. In order to carry out the activity smoothly, the company decided to set up a leading group for the celebration of the 60th anniversary of entrepreneurship, with Jiang Xiaomeng, chairman of the group company, as the group leader and Yu Jianhong, general manager of the group company, as the deputy group leader. The group members include Huang Jinlong, Zhang Fengliang, Xiang Chongping, Chen Tianci, Zhu Jianwei, Lan Xiaolong and Qin Xuping. There is a celebration working group. The series of commemorative activities mainly include media publicity with the theme of "publicizing peak achievements and establishing peak image"; carrying out manuscripts, calligraphy, painting, photography, speeches and other activities with the theme of "knowing peak and loving peak" and the history of Jianfeng Group's entrepreneurial development as the content; a series of cultural and sports activities with the theme of "strengthening physique and revitalizing peak; the activity of" sending warmth "with the theme of" caring for employees and caring for employees "; the group company with the theme of" infinite scenery at the peak"
2020
07-30
Determination of "60th Anniversary of Entrepreneurship" Series of Activities
In 1958, the first batch of peak people started from scratch and began to build the first cement plant in Jinhua at the foot of peak mountain. Today, 60 years later, the small cement plant has developed into a cross industry and cross regional listed company. In order to commemorate the 60th anniversary of Jianfeng's entrepreneurship, the company decided to organize a series of activities. The activity plan has been basically determined by the group company's office meeting, and an activity leading group led by Jiang Xiaomeng, chairman of the group company, has been established. The group office meeting discussed and decided that the commemorative activities are based on the principles of grand, simple and meaningful. While enlivening the company's cultural atmosphere, concentrating efforts, and enhancing the friendship and exchange of all employees, it also inherits and carries forward the essence of corporate culture accumulated over a long period of time. In order to carry out the activity smoothly, the company decided to set up a leading group for the celebration of the 60th anniversary of entrepreneurship, with Jiang Xiaomeng, chairman of the group company, as the group leader and Yu Jianhong, general manager of the group company, as the deputy group leader. The group members include Huang Jinlong, Zhang Fengliang, Xiang Chongping, Chen Tianci, Zhu Jianwei, Lan Xiaolong and Qin Xuping. There is a celebration working group. The series of commemorative activities mainly include media publicity with the theme of "publicizing peak achievements and establishing peak image"; carrying out manuscripts, calligraphy, painting, photography, speeches and other activities with the theme of "knowing peak and loving peak" and the history of Jianfeng Group's entrepreneurial development as the content; a series of cultural and sports activities with the theme of "strengthening physique and revitalizing peak; the activity of" sending warmth "with the theme of" caring for employees and caring for employees "; the group company with the theme of" infinite scenery at the peak"
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page